Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study-Reference-Cited by-同舟云学术

Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study

Published:2017-01-06 Issue:3 Volume:6 Page:e1277307
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Tan Yamin¹,Xiao Haowen²,Wu Depei³,Luo Yi¹,Lan Jianping⁴,Liu Qifa⁵^ORCID,Yu Kang⁶,Shi Jimin¹,He Jingsong¹,Zheng Weiyan¹,Lai Xiaoyu¹,Zhu Yuanyuan¹,Du Kaili¹,Ye Yishan¹,Zhao Yanmin¹,Zheng Gaofeng¹,Hu Yongxian¹,Han Xiaoyan¹,Zheng Yanlong¹,Wei Guoqing¹,Cai Zhen¹,Huang He¹

Affiliation:

1. Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, P.R. China

2. Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command (Guangzhou Liuhuaqiao Hospital), Guangzhou, Guangdong Province, P.R. China

3. Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, P.R. China

4. Department of Hematology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, P.R. China

5. Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, P.R. China

6. Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, P.R. China

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1277307

Reference41 articles.

1. Graft-versus-host disease

2. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment

3. How I treat refractory acute GVHD

4. First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ruxolitinib Plus Basiliximab Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease in Unrelated Cord Blood Transplantation: A Large-Scale Study;Transplantation and Cellular Therapy;2024-09

2. Ruxolitinib plus basiliximab therapy for steroid-refractory acute graft-versus-host disease in unrelated cord blood transplantation: a large-scale study;2024-03-21

3. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial;BMC Medicine;2024-02-27

4. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation;Cell Transplantation;2024-01

5. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study;Annals of Hematology;2023-07-20